CA2359285C - Atrial sensing and multiple site stimulation as intervention for atrial fibrillation - Google Patents
Atrial sensing and multiple site stimulation as intervention for atrial fibrillation Download PDFInfo
- Publication number
- CA2359285C CA2359285C CA002359285A CA2359285A CA2359285C CA 2359285 C CA2359285 C CA 2359285C CA 002359285 A CA002359285 A CA 002359285A CA 2359285 A CA2359285 A CA 2359285A CA 2359285 C CA2359285 C CA 2359285C
- Authority
- CA
- Canada
- Prior art keywords
- stimulation
- capture
- phase
- implantable cardiac
- cardiac stimulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/37—Monitoring; Protecting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/37—Monitoring; Protecting
- A61N1/371—Capture, i.e. successful stimulation
- A61N1/3712—Auto-capture, i.e. automatic adjustment of the stimulation threshold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
- A61N1/3622—Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
- A61N1/3624—Heart stimulators for treating or preventing abnormally high heart rate occurring in the atrium, i.e. atrial tachycardia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Electrotherapy Devices (AREA)
Abstract
Atrial sensing and stimulation as intervention for atrial fibrillation. The present invention relates to a method of atrial defibrillation. In a variety of protocols varying combinations of conventional and biphasic stimulation are applied at threshold and subthreshold levels. In a preferred embodiment, the implantable electronic stimulation device of the present invention includes multiple electrodes having stimulating and sensing capabilities. The small size of these electrodes allows for intravenous insertion into the patient.
Description
Title: ATRIAL SENSING AND MULTIPLE SITE STIMULATION AS
INTERVENTION FOR ATRIAL FIBRILLATION
Inventor: Morton M. Mower, M.D.
Field of the Invention 1 The present invention relates generally to electronic stimulation devices to control 2 the beating of hearts, especially hearts with pathologies that interfere with normal 3 rhythmicity, electrical conduction, and/or contractility. In particular, the present invention 4 relates to pacemakers used to overcome atrial fibrillation by use of 1) atrial sensing; 2) electrical test stimulation of the atria; and 3) multiple site stimulation in which the various 6 atrial areas are slowly entrained to a common beating rate to produce electrical/functional 7 conformity, i.e., cardioversion, with each case either eventuating in spontaneous reversion 8 to a normal atrial rhythm, or reduced energy requirement for reversion by electrical 9 countershock.
Background of the Invention 11 Morbidity associated with malfunctions of the atria, while not immediate, is high.
12 Atrial malfunctions of rhythmicity (e.g., atrial fibrillation, various atrial arrhythmias, A-V
13 block and other conduction abnormalities, etc.) can contribute to thrombosis, emboli, 14 stroke and/or heart failure, each of which can place a patient in significant peril.
Atrial Sensing. A variety of approaches have been developed which use 16 pacemakers to counter atrial malfunctions of rhythmicity, as well as attendant effects on 17 ventricular function. In addition, sophisticated approaches have been developed for 18 pacemaker systems to determine the nature of any particular ventricular malfunction, and 19 whether a malfunction originates in the atria or in the ventricles. One such approach uses ventricular sensing to measure/determine the probability density function (pdf) on a 21 moment-to-moment basis. For example, U.S. Patent No. 5,163,429 to Cohen discloses the 1 use of narrow window pdf data as but one criterion among several for assessing ventricular 2 cardiac function. The use of pdf data to determine ventricular fibrillation also is disclosed 3 in Implantable Cardioverter-Defibrillators (N.A. Estes III, A. Manolis & P.
Wang, ed.).
4 U.S. Patent No. 5,421,830 to Epstein, et al. (discussed further below) also discloses the use of pdf data as one set among a variety of data types that collectively are also used to assess 6 cardiac function. The use of probability density function data for assessing atrial cardiac 7 function has not been disclosed and presents its own unique difficulties as will be further 8 discussed.
INTERVENTION FOR ATRIAL FIBRILLATION
Inventor: Morton M. Mower, M.D.
Field of the Invention 1 The present invention relates generally to electronic stimulation devices to control 2 the beating of hearts, especially hearts with pathologies that interfere with normal 3 rhythmicity, electrical conduction, and/or contractility. In particular, the present invention 4 relates to pacemakers used to overcome atrial fibrillation by use of 1) atrial sensing; 2) electrical test stimulation of the atria; and 3) multiple site stimulation in which the various 6 atrial areas are slowly entrained to a common beating rate to produce electrical/functional 7 conformity, i.e., cardioversion, with each case either eventuating in spontaneous reversion 8 to a normal atrial rhythm, or reduced energy requirement for reversion by electrical 9 countershock.
Background of the Invention 11 Morbidity associated with malfunctions of the atria, while not immediate, is high.
12 Atrial malfunctions of rhythmicity (e.g., atrial fibrillation, various atrial arrhythmias, A-V
13 block and other conduction abnormalities, etc.) can contribute to thrombosis, emboli, 14 stroke and/or heart failure, each of which can place a patient in significant peril.
Atrial Sensing. A variety of approaches have been developed which use 16 pacemakers to counter atrial malfunctions of rhythmicity, as well as attendant effects on 17 ventricular function. In addition, sophisticated approaches have been developed for 18 pacemaker systems to determine the nature of any particular ventricular malfunction, and 19 whether a malfunction originates in the atria or in the ventricles. One such approach uses ventricular sensing to measure/determine the probability density function (pdf) on a 21 moment-to-moment basis. For example, U.S. Patent No. 5,163,429 to Cohen discloses the 1 use of narrow window pdf data as but one criterion among several for assessing ventricular 2 cardiac function. The use of pdf data to determine ventricular fibrillation also is disclosed 3 in Implantable Cardioverter-Defibrillators (N.A. Estes III, A. Manolis & P.
Wang, ed.).
4 U.S. Patent No. 5,421,830 to Epstein, et al. (discussed further below) also discloses the use of pdf data as one set among a variety of data types that collectively are also used to assess 6 cardiac function. The use of probability density function data for assessing atrial cardiac 7 function has not been disclosed and presents its own unique difficulties as will be further 8 discussed.
9 Electrical Test Stimulation ofAtria. In a few limited cases, pacemaker protocols have been employed in which electrical test stimuli are applied to the atria, and the 11 physiological responses thereto are monitored to aid in the determination of the best or 12 most appropriate protocol to initiate, cure, or ameliorate the existing cardiac malfunction.
13 For example, U.S. Patent No. 5,620,471 to Duncan discloses three basic protocols for 14 determining whether observed ventricular irregularities are actually caused by atrial arrhythmias. One protocol includes atrial electrical test stimulation, and all three protocols 16 monitor both atrial and ventricular rhythms for three parameters: rates of atrial and 17 ventricular firing, stability of firing/beating in atria and ventricles, and whether or not 18 ventricular firing tracks atrial firing. In the first protocol, when the ventricular firing rate 19 is less than the atrial firing rate (indicating no ventricular tracking of atrial beats), and firing rates are stable, then ventricular tachycardia is presumed, and ventricular stimulation 21 is applied. On the other hand (second protocol), if the ventricular firing rate is not stable, 22 then atrial arrhythmia is presumed, and atrial stimulation is applied. The third protocol is 23 based on the fact that, when the ventricular firing rate equals the atrial firing rate, there 1 may or may not be ventricular tracking of atrial firing. Whether or not there is ventricular 2 tracking is determined by the presence or not of ventricular tracking following premature 3 atrial stimulation by the pacemaker. If there is ventricular tracking of atrial firing, the 4 arrhythmic mechanism is presumed to be atrial tachycardia. However, if there is no ventricular tracking of atrial firing, then ventricular tachycardia is presumed, and 6 ventricular stimulation is performed.
7 U.S. Patent No. 5,421,830 to Epstein, et al. discloses a general means for 8 recording, testing, and analyzing cardiac function based on data from -- and electrical test 9 stimulation via -- a patient's pacemaker, as well as data from additional sensors detecting hemodynamic or other body functions. Total intracardiac electrograms (reflecting both 11 atrial and ventricular functional status) or just selected data (e.g., P-P
or R-R intervals, 12 heart rate, arrhythmia duration, slew rate, probability density function, etc.) may be 13 recorded and analyzed. The patient's atrial and ventricular responses to electrical test 14 pulses may also be recorded. In sum, this system provides a means to more easily tailor settings for pacemakers to achieve optimal settings for the specific patient or for the 16 specific situation (e.g., during exercise or exertion) of a given patient.
17 U.S. Patent No. 5,215,083 to Drane, et al. also discloses the use of electrical test 18 stimulation to aid in the fine tuning and evaluation of different possible stimulation 19 protocols for a patient's heart. In particular, electrical test pulses are employed to induce ventricular fibrillation or tachycardia for use in evaluating the effectiveness of alternative 21 programmed therapies.
22 Multiple Site Atrial Stimulation. The use of multiple site atrial stimulation has 23 been disclosed for various purposes, such as defibrillation, cardioversion, pacing, and dc 1 field production. One example is provided by U.S. Patent No. 5,562,708 to Combs, et al., 2 which discloses the employment of large surface electrodes (each effectively comprising 3 multiple electrodes) that are implanted to one or both atria for providing extended, low 4 energy electrical impulses. The electrical impulses are applied simultaneously at multiple sites over atrial surfaces, and atrial fibrillation is interrupted by gradually entraining 6 greater portions of atrial tissue. These pacemaker electrodes may be used for various 7 purposes in addition to pacing, such as conventional defibrillation and cardioversion.
8 U.S. Patent No. 5,649,966 to Noren, et al. discloses the use of multiple electrodes 9 for the purpose of applying a subthreshold dc field to overcome fibrillation. The rate of application of the dc field is sufficiently low so that no action potential is triggered.
11 Polarity may also be changed periodically. In one embodiment, four electrodes are 12 positioned within a single plane in the heart, which permits a dipole field in virtually any 13 direction within that plane.
14 U.S. Patent No. 5,411,547 to Causey. III discloses the use of sets of complex mesh patch electrodes, in which each electrode comprises an anode patch and a cathode patch, 16 for purposes of cardioversion-defibrillation. Bidirectional cardiac shocking is permitted 17 by these electrodes.
18 U.S. Patent No. 5,391,185 to Kroll discloses the use of multiple electrodes to effect 19 atrial defibrillation. The possibility of inducing ventricular fibrillation during the course of atrial defibrillation is greatly reduced by synchronizing the atrial stimulation to fall within 21 the QRS phase of the ventricular cycle.
22 U.S. Patent No. 5,181,511 to Nickolls, et al. discloses the use of multiple 23 electrodes in antitachycardia pacing therapy. The electrodes not only each serve an 1 electrical sensing role (to locate the site of an ectopic focus), but also function in concert to 2 create a virtual electrode for stimulating at the site of an ectopic focus.
3 Existing Needs. In the area of atrial malfunctions of rhythmicity what is needed is 4 a means to entrain multiple atrial sites, but also in combination with an atrial sensing/
measurement capability that is coupled with atrial test stimulation and analysis capability.
6 Atrial test stimulation and analysis capability is needed to provide better determination of 7 the nature of the malfunction and the most probable or efficacious corrective therapy to 8 undertake. Furthermore, the use of atrial test stimulation is critically needed for the 9 fundamental reason that the physician cannot know a priori how a given heart (or a given heart under a particular medical or pathological condition) will respond to a selected 11 stimulation regime, even if that selected stimulation regime would work generally for 12 other cardiac patients. Thus, a trial-and-error testing capability needs to be available for 13 pacemakers whose traditional stimulation regimes do not work for the occasional 14 refractory patient. The multiple site stimulation capability is needed in order to more quickly and efficiently cardioconvert the atria in the face of arrhythmia, fibrillation, etc.
16 Atrial sensing and use of measurement data are needed to better provide the physician 17 and/or the circuit logic of the pacemaker with information as to the physiological state of 18 the heart; i.e., whether there is atrial arrhythmia or fibrillation, where an ectopic focus is 19 located, etc. Thus, what is needed is a pacemaker that combines all three of these elements: atrial sensing and measurement capability, atrial electrical test stimulation and 21 analysis capability, and multiple site stimulation capability.
22 Lastly, a need also exists for a stimulation protocol which can travel more quickly 23 across the myocardium and which provides improved cardiac entrainment along with the 1 ability to entrain portions of the heart from a greater distance.
2 Summary of the Invention 3 It therefore is an object of the present invention to provide a pacemaker that is 4 capable of pacing atria from multiple sites.
It is another object of the present invention to provide a pacemaker that is capable 6 of slowly entraining atria by stimulating the atria at multiple sites to produce electrical and 7 functional conformity of the atria, with resulting increased pumping efficiency of the heart.
8 It is yet another object of the present invention to provide a pacemaker that is 9 capable of detecting the presence of atrial fibrillation and atrial arrhythmias by stimulating the atria and observing and measuring the consequent effects on atrial and ventricular 11 function.
12 It is a further object of the present invention to provide a pacemaker that is capable 13 of obtaining and analyzing probability density function data from atria in order to 14 determine atrial rates of beating and to assess atrial physiological function.
It is a further object of the present invention to provide an electronic stimulation 16 device, for stimulating the atria from multiple sites, where the electrodes of the electronic 17 stimulation device can be inserted intravenously.
18 It is a further object of the present invention to provide an electronic stimulation 19 device, for stimulating the atria from multiple sites, where each electrode of the device has an independent generator.
21 It is a fixrther object of the present invention to provide an electronic stimulation 22 device for stimulating the atria from multiple sites, where each site is entrained separately 23 and quickly brought to the same phase.
It is a further object of the present invention to provide an electronic stimulation device for stimulating the atria from multiple sites, to sequence the sites to mimic a normal heart beat.
It is a further object of the present invention to determine cardiac capture by monitoring cardiac activity and noting when the baseline of such activity is off zero.
It is a further object of the present invention to decrease threshold rises due to a build up of fibrous tissue.
In accordance with one aspect of the present invention, there is provided an implantable cardiac stimulator to perform atrial defibrillation, the cardiac stimulator comprising: sensor adapted to sense the onset of atrial fibrillation; recorder adapted to record a baseline of cardiac activity; processor adapted to determining whether capture has occurred; and electrodes adapted to stimulate the atrium after the onset of atrial fibrillation has been sensed, wherein, in the event it is determined that capture has not occurred, the atrium is stimulated using a pre-capture stimulation protocol, wherein, in the event it is determined that capture has occurred, the atrium is stimulated using a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, the procedure being selected from the group consisting of: pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
In accordance with a second aspect of the present invention, there is provided an apparatus for electrical cardiac pacing comprising: a plurality of electrodes adapted to be disposed proximate atrial tissue; a sense amplifier connected to at least one of the plurality of electrodes to sense atrial fibrillation; a memory in electrical communication with the sense amplifier, for recording a baseline of cardiac activity; an electrical stimulation driver, connected to at least one of the plurality of electrodes, to stimulate atrial tissue; and processor circuitry programmed to determine status of pacing capture;
wherein, in the event that atrial fibrillation is sensed, the electrical stimulation driver uses a pre-capture stimulation protocol, wherein, in the event that capture status is determined, the electrical stimulation driver uses a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, and wherein the procedure is selected from the group consisting of: pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
The present invention accomplishes the above objectives by providing a cardiac pacemaker with a unique constellation of features and capabilities. In particular, a means for entraining multiple atrial sites is provided by the use of multiple electrodes. The multiple electrodes not only permit multi-site stimulation capability, but also multi-site sensing (including pdf measurement) capability, which, by triangulation, essentially provides the ability to determine the site(s) of any atrial ectopic focus. The 7a = ' .
multi-site stimulation capability inherently provides a system poised for more efficient entrainment and/or cardioconversion of the atria in the face of arrhythmia, fibrillation, etc. Combined with this multi-site stimulation/sensing capability is the means to execute trial-and-error testing and analysis to determine the best general stimulation protocol, to fine tune a given protocol, or to adjust a protocol in response to changes in the physiological/pathological status of the patient in general and/or the patient's heart in particular.
Incorporating the use of biphasic stimulation with the present invention provides the additional benefits of reducing cardiac inflammation damage, reducing or eliminating threshold rises due to the buildup of fibrous tissue and extending battery life of the electrodes.
7b 1 In addition, the ability to conduct trial-and-error testing, including the analysis of 2 the data derived therefrom, permits more thorough and more definitive determination of 3 the physiological status of the heart; this determination can practically approach a 4 moment-to-moment basis when analysis is automated by appropriate software for the purpose.
6 In sum, the present invention provides a cardiac pacemaker that has greater 7 functional capabilities for the patient's atria than current technologies allow. The greater 8 atrial "coverage" from the strategic placement of multiple electrodes permits faster 9 correction of atrial arrhythmia, fibrillation, etc. Similarly, the use of multi-site electrodes permits more accurate sensing, including the capability of locating the site(s) of any atrial 11 ectopic focus so as to better apply corrective stimulation procedures. In addition, the 12 ability to apply trial-and-error testing/analytical procedures permits quicker analysis and 13 correction of malfunctions of electrical conduction, cardiac contractility, rhythmicity, etc.
14 Thus, the present invention constitutes an advance in cardiac care procedures as they relate to atrial pacemakers. The end result for the patient is better treatment, and, hence, a better 16 prognosis from the better and faster treatment.
17 The method and apparatus relating to biphasic pacing comprises a first and second 18 stimulation phase, with each stimulation phase having a polarity, amplitude, shape, and 19 duration. In a preferred embodiment, the first and second phases have differing polarities.
In one alternative embodiment, the two phases are of differing amplitude. In a second 21 alternative embodiment, the two phases are of differing duration. In a third alternative 22 embodiment, the first phase is in a chopped wave form. In a fourth alternative 23 embodiment, the amplitude of the first phase is ramped. In a fifth alternative embodiment 1 the first phase is administered over 200 milliseconds after completion of a cardiac 2 beating/pumping cycle. In a preferred alternative embodiment, the first phase of 3 stimulation is an anodal pulse at maximum subthreshold amplitude for a long duration, 4 and the second phase of stimulation is a cathodal pulse of short duration and high amplitude. It is noted that the aforementioned alternative embodiments can be combined 6 in differing fashions. It is also noted that these alternative embodiments are intended to be 7 presented by way of example only, and are not limiting.
8 Enhanced myocardial function is obtained through the biphasic stimulation of the 9 present invention. The combination of cathodal with anodal pulses of either a stimulating or conditioning nature, preserves the improved conduction and contractility of anodal 11 stimulation while eliminating the drawback of increased stimulation threshold. The result 12 is a depolarization wave of increased propagation speed. This increased propagation speed 13 results in increased synchronization and reduced heterogenicity of myocardial 14 depolarization resulting in superior blood flow and contraction. Improved stimulation at a lower voltage level also results in: 1/ reduction in scar tissue buildup thereby reducing the 16 tendency of the capture threshold to rise; 2/ reduction in power consumption leading to 17 increased life for pacemaker batteries; and 3/ decreased potential for patient discomfort 18 due to stimulation of the phrenic or diaphragmatic plexus or due to intercostal muscle 19 pacing.
Brief Description of the Drawings 21 Figure 1 illustrates the location of leads and electrodes in relation to a human heart.
22 Figure 2 illustrates an alternative location of leads and electrodes in relation to a 23 human heart.
A Figure 2A illustrates a block diagram of the major functional components of the 2 implanted pacemaker.
3 Figure 3 is a schematic representation of leading anodal biphasic stimulation.
4 Figure 4 is a schematic representation of leading cathodal biphasic stimulation.
Figure 5 is a schematic representation of leading anodal stimulation of low level 6 and long duration, followed by conventional cathodal stimulation.
7 Figure 6 is a schematic representation of leading anodal stimulation of ramped low 8 level and long duration, followed by conventional cathodal stimulation.
9 Figure 7 is a schematic representation of leading anodal stimulation of low level and short duration, administered in series followed by conventional cathodal stimulation.
11 Figure 8 illustrates the practice of the present invention.
12 Description of the Preferred Embodiments 13 Electrical stimulation is delivered via lead(s) or electrode(s). These leads can be 14 epicardial (external surface of the heart) or endocardial (internal surface of the heart) or any combination of epicardial and endocardial. Leads are well known to those skilled in 16 the art. Lead systems can be unipolar or bipolar. A unipolar lead has one electrode on the 17 lead itself, the cathode. Current flows from the cathode, stimulates the heart, and returns 18 to the anode on the casing of the pulse generator to complete the circuit.
A bipolar lead 19 has two poles on the lead a short distance from each other at the distal end, and both electrodes lie within the heart.
21 Figure 1 illustrates a plan view of implantable electronic stimulation device 102 22 and its associated lead and electrode system, in conjunction with human heart 104. As 23 illustrated, the device includes right atrial appendage lead 106, right atrial septal lead 108, 1 first coronary sinus lead 110 and second coronary sinus lead 112. Each of these multiple 2 small electrodes can be inserted intravenously and includes an independent generator.
3 Figure 2 illustrates a plan view of implantable electronic stimulation device 102 4 illustrating an alternative location of leads and electrodes in relation to human heart 104.
As illustrated, the device includes right atrial appendage lead 106, right atrial septal lead 6 108, first coronary sinus lead 110, second coronary sinus lead 112 and left free wall lead 7 204. Each of these multiple small electrodes can be inserted intravenously and includes an 8 independent generator. Because of the use of independent generators, each electrode can 9 be timed differently. In a preferred embodiment, left free wall lead 204 is placed by piercing septum 206 and passing left free wall lead 204 through the septum to the left side 11 of the heart. The aforementioned placement of leads is for illustration purposes only, and 12 is not intended as a limitation. It is contemplated that multiple leads placed in a variety of 13 locations could be used.
14 Each site (area of lead placement) can be entrained separately, and then brought to the same phase. In a preferred embodiment each site is gradually brought to the same 16 phase; however, certain situations could require that each site is quickly brought to the 17 same phase. In an alternative embodiment, the sites can be sequenced to mimic a normal 18 heart beat. In addition to allowing multi-site stimulation capability, the sensing circuits of 19 each electrode also allow for multi-site sensing. Through triangulation the multi-site sensing provides a means for determining the site(s) of any atrial ectopic focus.
21 Referring to Figure 2A, a block diagram shows the major functional components 22 of the implanted pacemaker 102. Pacing/control circuitry 500, in conjunction with 23 microprocessor 501 detects the occurrence of tachycardia (and/or bradycardia) and in 1 response thereto controls the delivery of the various pacing therapies available via control 2 bus 512. The microprocessor 501 also detects the occurrence of atrial fibrillation.
3 Detection of atrial fibrillation may be accomplished by the microprocessor 501 using any 4 of the various detection methodologies known to the art. Generally, atrial fibrillation may be detected in response to an extended series of high rate atrial depolarizations. If greater 6 specificity for atrial fibrillation is desired, analysis of regularity of rate waveform 7 morphology may also be employed. Termination of atrial fibrillation may be detected in 8 response to a decrease in the rate of atrial depolarizations and/or an increase in their 9 regularity.
The operation of the microprocessor 501 is controlled by programming stored in a 11 read only memory 505 and in a random access memory 503. The operation of the device 12 may be altered by the physician by altering the programming stored in the memory 503, 13 using control and telemetry circuitry conventional in implantable stimulators.
14 Communication to and from the microprocessor 501, the memories 503, 505, and the control logic 500 is accomplished using an address/data bus 507.
16 The atrial sensing circuit 509 can be any conventional cardiac sense amplifier 17 circuits equivalent to any atrial cardiac sensing circuits employed in previous devices 18 known in the art.
19 The implanted pacemaker 102 has a switch matrix 516 that allows selective delivery of pacing pulses from the atrial pacing driver 514 to the electrodes.
The matrix 21 516 may be embodied as simply a collection of one or more FET and/or SCR
switches 22 activated under control of the pacing/control circuitry 500 to selectively pacing circuitry 23 516 to electrodes 106 and 108, or to electrodes 110 and 112, or other combinations of the 24 electrodes. Thus, atrial anti-tachycardia (or anti-bradycardia pacing) is performed using any combination of the deployed pacing electrodes.
1 In a preferred embodiment, stimulation is administered at threshold until capture 2 has occurred, at which time stimulation is administered at a subthreshold level. In 3 alternative embodiments, stimulation is: (1) initiated at threshold and remains at threshold;
4 (2) initiated subthreshold and remains subthreshold; (3) conventional prior to capture and then biphasic; (4) biphasic prior to capture and then conventional or (5) biphasic 6 throughout.
7 Threshold refers to the minimum voltage level (or pulse width using a fixed 8 voltage) which succeeds in stimulating (capturing) the myocardium. To capture is to 9 produce a driven beat because of the stimulus given. Thus, in the absence of the pulse, the beat would not have been produced. Pulses which do not capture are subthreshold, (even 11 though they may be shown to perturb the membrane potential somewhat, and transiently).
12 Subthreshold pulses thus may affect subsequent conduction, but not by the mechanism of 13 initiating a driven beat. Generally, to determine threshold, voltage (or pulse width) is 14 varied (upward or downward) until capture is gained or lost.
Conventional stimulation is well known to those skilled in the art and comprises 16 monophasic waveforms (cathodal or anodal) as well as multiphasic waveforms wherein 17 the nonstimulating pulses are of a minimal magnitude and are used, for example, to 18 dissipate a residual charge on an electrode.
19 Figures 3 through 7 depict a range of biphasic stimulation protocols. These protocols have been disclosed in United States Patent Application No.
08/699,552 to 21 Mower, which is herein incorporated by reference in its entirety.
22 Figure 3 depicts biphasic electrical stimulation wherein a first stimulation phase 23 comprising anodal stimulus 302 is administered having amplitude 304 and duration 306.
1 This first stimulation phase is immediately followed by a second stimulation phase 2 comprising cathodal stimulation 308 of equal intensity and duration.
3 Figure 4 depicts biphasic electrical stimulation wherein a first stimulation phase 4 comprising cathodal stimulation 402 having amplitude 404 and duration 406 is administered. This first stimulation phase is immediately followed by a second 6 stimulation phase comprising anodal stimulation 408 of equal intensity and duration.
7 Figure 5 depicts a preferred embodiment of biphasic stimulation wherein a first 8 stimulation phase, comprising low level, long duration anodal stimulation 502 having 9 amplitude 504 and duration 506, is administered. This first stimulation phase is immediately followed by a second stimulation phase comprising cathodal stimulation 508 11 of conventional intensity and duration. In differing alternative embodiments, anodal 12 stimulation 502 is: 1) at maximum subthreshold amplitude; 2) less than three volts; 3) of a 13 duration of approximately two to eight milliseconds; and/or 4) administered over 200 14 milliseconds post heart beat. Maximum subthreshold amplitude is defined for purposes of this application as the maximum stimulation amplitude that can be administered without 16 eliciting a contraction. In a preferred embodiment, anodal stimulation is approximately 17 two volts for approximately three milliseconds duration. In differing alternative 18 embodiments, cathodal stimulation 508 is: 1) of a short duration; 2) approximately 0.3 to 19 1.5 milliseconds; 3) of a high amplitude; 4) in the approximate range of three to twenty volts; and/or 5) of a duration less than 0.3 millisecond and at a voltage greater than twenty 21 volts. In a preferred embodiment, cathodal stimulation is approximately six volts 22 administered for approximately 0.4 millisecond. In the manner disclosed by these 23 embodiments, as well as those alterations and modifications which can become obvious 1 upon the reading of this specification, a maximum membrane potential without activation 2 is achieved in the first phase of stimulation.
3 Figure 6 depicts an alternative preferred embodiment of biphasic stimulation 4 wherein a first stimulation phase, comprising anodal stimulation 602, is administered over period 604 with rising intensity level 606. The ramp of rising intensity level 606 can be 6 linear or non-linear, and the slope can vary. This anodal stimulation is immediately 7 followed by a second stimulation phase comprising cathodal stimulation 608 of 8 conventional intensity and duration. In alternative embodiments, anodal stimulation 602:
9 (1) rises to a maximum subthreshold amplitude less than three volts; (2) is of a duration of approximately two to eight milliseconds; and/or (3) is administered over 200 milliseconds 11 post heart beat. In yet other alternative embodiments, cathodal stimulation 608 is: (1) of a 12 short duration; (2) approximately 0.3 to 1.5 milliseconds; (3) of a high amplitude; (4) in 13 the approximate range of three to twenty volts; and/or (5) of a duration less than 0.3 14 milliseconds and at a voltage greater than twenty volts. In the manner disclosed by these embodiments, as well as those alterations and modifications which can become obvious 16 upon the reading of this specification, a maximum membrane potential without activation 17 is achieved in the first phase of stimulation.
18 Figure 7 depicts biphasic electrical stimulation wherein a first stimulation phase, 19 comprising series 702 of anodal pulses, is administered at amplitude 704.
In one embodiment, rest period 706 is of equal duration to stimulation period 708, and is 21 administered at baseline amplitude. In an alternative embodiment, rest period 706 is of a 22 differing duration than stimulation period 708, and is administered at baseline amplitude.
23 Rest period 706 occurs after each stimulation period 708, with the exception that a second A stimulation phase, comprising cathodal stimulation 710 of conventional intensity and 2 duration, immediately follows the completion of series 702. In alternative embodiments:
3 (1) the total charge transferred through series 702 of anodal stimulation is at the maximum 4 subthreshold level; and/or (2) the first stimulation pulse of series 702 is administered over 200 milliseconds post heart beat. In yet other alternative embodiments, cathodal 6 stimulation 710 is: (1) of a short duration; (2) approximately 0.3 to 1.5 milliseconds; (3) of 7 a high amplitude; (4) in the approximate range of three to twenty volts, and/or (5) of a 8 duration less than 0.3 milliseconds and at a voltage greater than twenty volts.
9 Figure 8 illustrates the practice of the present invention. Sensing is used to determine the existence of atrial fibrillation 802. Sensing can be direct or indirect. For 11 example, direct sensing can be based on data from multiple atrial sensing electrodes. The 12 sensing electrodes sense the cardiac activity as depicted by electrical signals. For example, 13 as is known in the art, R-waves occur upon the depolarization of ventricular tissue and P-14 waves occur upon the depolarization of atrial tissue. By monitoring these electrical signals the control/timing circuit of the ICD can determine the rate and regularity of the patient's 16 heart beat, and thereby determine whether the heart is undergoing arrhythmia. This 17 determination can be made by determining the rate of the sensed R-waves and/or P-waves 18 and comparing this determined rate against various reference rates.
19 Direct sensing can be based upon varying criteria; such as, but not limited to, primary rate, sudden onset, and stability. The sole criteria of a primary rate sensor is the 21 heart rate. When applying the primary rate criteria, if the heart rate should exceed a 22 predefined level, then treatment is begun. Sensing electronics set to sudden onset criteria 23 ignore those changes which occur slowly, and initiate treatment when there is a sudden 1 change such as immediate paroxysmal arrhythmia. This type of criteria would thus 2 discriminate against sinus tachycardia. Stability of rate can also be an important criteria.
3 For example, treatment with a ventricular device would not be warranted for a fast rate 4 that varies, here treatment with an atrial device would be indicated.
In alternative embodiments, sensing can be indirect. Indirect sensing can be based 6 on any of various functional parameters such as arterial blood pressure, rate of the 7 electrocardiogram deflections or the probability density function (pdf) of the 8 electrocardiogram. While it has been known in the art to apply pdf to the global 9 electrocardiogram and/or to the R wave, it has been unexpectedly discovered that pdf of the baseline is also indicated for the determination of atrial abnormalities.
Here, the 11 electrodes are specific to the atrium and data related to the R wave is canceled out. Thus, 12 whether or not to administer treatment can also be affected by pdf monitoring of the time 13 the signal spends around the baseline.
14 Lastly, to determine whether an arrhythmia comes from the atria or the ventricles, a test impulse(s) can be given to one chamber to see if capture occurs and perturbs the 16 rhythm. For example, in a ventricular rhythm, an atrial test impulse can capture the 17 atrium, but the ventricular rhythm will continue unchanged afterwards. In an atrial 18 rhythm, (or Sinus rhythm), if the atrial test pulse captures, the timing of all subsequent 19 beats is changed. To determine if a pulse captures, the baseline immediately after the beat can be examined to determine if it is different from zero (or from a baseline template). If 21 so, the beat can be inferred to have captured. In addition, the pdf pattern of the rhythm can 22 be shown to have changed, inferring capture.
23 Thus, in a preferred embodiment, sensing electronics are based upon multiple 1 criteria. In addition, the present invention envisions devices working in more than one 2 chamber such that appropriate treatment can be administered to either the atrium or the 3 ventricle in response to sensing electronics based upon a variety of criteria, including those 4 described above as well as other criteria known to those skilled in the art.
If atrial fibrillation occurs, a baseline of cardiac activity or a template can be 6 recorded 804. The template can be based on parameters such as electrocardiogram data, 7 mechanical motion and/or probability density function data. In an alternative embodiment, 8 the template is established after capture has occurred.
9 Pacing is initiated 806. In a preferred embodiment, stimulation is administered at threshold until capture has occurred, at which time stimulation is administered at a 11 subthreshold level. In alternative embodiments, stimulation is: (1) initiated at threshold 12 and remains at threshold; (2) initiated subthreshold and remains subthreshold; (3) 13 conventional prior to capture and then biphasic; (4) biphasic prior to capture and then 14 conventional or (5) biphasic throughout.
The atrium is monitored throughout this initial pacing period to determine the 16 status of capture 808. Capture can be determined by multiple means. First, capture or the 17 loss thereof, can be determined by monitoring cardiac rhythm. Loss of capture can result 18 in a change in timing of the heart beat.
19 Second, capture or the loss thereof, can be determined through monitoring the previously described template. Where the template is established pre-stimulation, a 21 change in the baseline signifies capture. Where the template is established after capture 22 has occurred, a change in the template characteristics signifies loss of capture. The 23 templates can be established and/or updated at any time.
I Once capture occurs the stitnulntion protocol of the eatrained sites is adjusted 8]Q.
2 In a first embodiment, the stimulation rates of the entrained sites are slowed 3 siraultaneously, and then stopped. In a second emboditnent, the spread of conduction is 4 slowed. In a third embodiment, the stimulation speed is increased and stimulation is then stopped. In addition to adjusting stimulation .rates upon the occurrence of capture, the 6 stimulation protocol can also be adjusted such that (1) if stimWation of a conventional 7 nature was administered prior to capture, biphasic stimulation is administered post-8 capture; (2) if bipbasic stimulation was administered prior to capture, conventional 9 stimulation is administered post-capture or (3) if biphasic stimulatioja was administered prior to capture, biphasic stimulation continues to be administered post-capture.
11 Having thus described the basic concept of the invention, it will be readily agparent 12 to those skilled in the art that the foregoing detailed disclosure is intended to be presented 13 by way of example only, and is not limiting. Various alterations, improvements and 14 modifications will occur and are intended to those skilled in the art, but are not expressly stated herein. These modifications, alterations and improvements are intended to be 16 suggested hereby, and. within the scope of the invention. Futher, the pacing pulses 17 described in this specification are well within the capabilities of existing pacemaker l 8 electronics with appropriate programming. Accordingly, the invention is limited only by 19 the following claims.
13 For example, U.S. Patent No. 5,620,471 to Duncan discloses three basic protocols for 14 determining whether observed ventricular irregularities are actually caused by atrial arrhythmias. One protocol includes atrial electrical test stimulation, and all three protocols 16 monitor both atrial and ventricular rhythms for three parameters: rates of atrial and 17 ventricular firing, stability of firing/beating in atria and ventricles, and whether or not 18 ventricular firing tracks atrial firing. In the first protocol, when the ventricular firing rate 19 is less than the atrial firing rate (indicating no ventricular tracking of atrial beats), and firing rates are stable, then ventricular tachycardia is presumed, and ventricular stimulation 21 is applied. On the other hand (second protocol), if the ventricular firing rate is not stable, 22 then atrial arrhythmia is presumed, and atrial stimulation is applied. The third protocol is 23 based on the fact that, when the ventricular firing rate equals the atrial firing rate, there 1 may or may not be ventricular tracking of atrial firing. Whether or not there is ventricular 2 tracking is determined by the presence or not of ventricular tracking following premature 3 atrial stimulation by the pacemaker. If there is ventricular tracking of atrial firing, the 4 arrhythmic mechanism is presumed to be atrial tachycardia. However, if there is no ventricular tracking of atrial firing, then ventricular tachycardia is presumed, and 6 ventricular stimulation is performed.
7 U.S. Patent No. 5,421,830 to Epstein, et al. discloses a general means for 8 recording, testing, and analyzing cardiac function based on data from -- and electrical test 9 stimulation via -- a patient's pacemaker, as well as data from additional sensors detecting hemodynamic or other body functions. Total intracardiac electrograms (reflecting both 11 atrial and ventricular functional status) or just selected data (e.g., P-P
or R-R intervals, 12 heart rate, arrhythmia duration, slew rate, probability density function, etc.) may be 13 recorded and analyzed. The patient's atrial and ventricular responses to electrical test 14 pulses may also be recorded. In sum, this system provides a means to more easily tailor settings for pacemakers to achieve optimal settings for the specific patient or for the 16 specific situation (e.g., during exercise or exertion) of a given patient.
17 U.S. Patent No. 5,215,083 to Drane, et al. also discloses the use of electrical test 18 stimulation to aid in the fine tuning and evaluation of different possible stimulation 19 protocols for a patient's heart. In particular, electrical test pulses are employed to induce ventricular fibrillation or tachycardia for use in evaluating the effectiveness of alternative 21 programmed therapies.
22 Multiple Site Atrial Stimulation. The use of multiple site atrial stimulation has 23 been disclosed for various purposes, such as defibrillation, cardioversion, pacing, and dc 1 field production. One example is provided by U.S. Patent No. 5,562,708 to Combs, et al., 2 which discloses the employment of large surface electrodes (each effectively comprising 3 multiple electrodes) that are implanted to one or both atria for providing extended, low 4 energy electrical impulses. The electrical impulses are applied simultaneously at multiple sites over atrial surfaces, and atrial fibrillation is interrupted by gradually entraining 6 greater portions of atrial tissue. These pacemaker electrodes may be used for various 7 purposes in addition to pacing, such as conventional defibrillation and cardioversion.
8 U.S. Patent No. 5,649,966 to Noren, et al. discloses the use of multiple electrodes 9 for the purpose of applying a subthreshold dc field to overcome fibrillation. The rate of application of the dc field is sufficiently low so that no action potential is triggered.
11 Polarity may also be changed periodically. In one embodiment, four electrodes are 12 positioned within a single plane in the heart, which permits a dipole field in virtually any 13 direction within that plane.
14 U.S. Patent No. 5,411,547 to Causey. III discloses the use of sets of complex mesh patch electrodes, in which each electrode comprises an anode patch and a cathode patch, 16 for purposes of cardioversion-defibrillation. Bidirectional cardiac shocking is permitted 17 by these electrodes.
18 U.S. Patent No. 5,391,185 to Kroll discloses the use of multiple electrodes to effect 19 atrial defibrillation. The possibility of inducing ventricular fibrillation during the course of atrial defibrillation is greatly reduced by synchronizing the atrial stimulation to fall within 21 the QRS phase of the ventricular cycle.
22 U.S. Patent No. 5,181,511 to Nickolls, et al. discloses the use of multiple 23 electrodes in antitachycardia pacing therapy. The electrodes not only each serve an 1 electrical sensing role (to locate the site of an ectopic focus), but also function in concert to 2 create a virtual electrode for stimulating at the site of an ectopic focus.
3 Existing Needs. In the area of atrial malfunctions of rhythmicity what is needed is 4 a means to entrain multiple atrial sites, but also in combination with an atrial sensing/
measurement capability that is coupled with atrial test stimulation and analysis capability.
6 Atrial test stimulation and analysis capability is needed to provide better determination of 7 the nature of the malfunction and the most probable or efficacious corrective therapy to 8 undertake. Furthermore, the use of atrial test stimulation is critically needed for the 9 fundamental reason that the physician cannot know a priori how a given heart (or a given heart under a particular medical or pathological condition) will respond to a selected 11 stimulation regime, even if that selected stimulation regime would work generally for 12 other cardiac patients. Thus, a trial-and-error testing capability needs to be available for 13 pacemakers whose traditional stimulation regimes do not work for the occasional 14 refractory patient. The multiple site stimulation capability is needed in order to more quickly and efficiently cardioconvert the atria in the face of arrhythmia, fibrillation, etc.
16 Atrial sensing and use of measurement data are needed to better provide the physician 17 and/or the circuit logic of the pacemaker with information as to the physiological state of 18 the heart; i.e., whether there is atrial arrhythmia or fibrillation, where an ectopic focus is 19 located, etc. Thus, what is needed is a pacemaker that combines all three of these elements: atrial sensing and measurement capability, atrial electrical test stimulation and 21 analysis capability, and multiple site stimulation capability.
22 Lastly, a need also exists for a stimulation protocol which can travel more quickly 23 across the myocardium and which provides improved cardiac entrainment along with the 1 ability to entrain portions of the heart from a greater distance.
2 Summary of the Invention 3 It therefore is an object of the present invention to provide a pacemaker that is 4 capable of pacing atria from multiple sites.
It is another object of the present invention to provide a pacemaker that is capable 6 of slowly entraining atria by stimulating the atria at multiple sites to produce electrical and 7 functional conformity of the atria, with resulting increased pumping efficiency of the heart.
8 It is yet another object of the present invention to provide a pacemaker that is 9 capable of detecting the presence of atrial fibrillation and atrial arrhythmias by stimulating the atria and observing and measuring the consequent effects on atrial and ventricular 11 function.
12 It is a further object of the present invention to provide a pacemaker that is capable 13 of obtaining and analyzing probability density function data from atria in order to 14 determine atrial rates of beating and to assess atrial physiological function.
It is a further object of the present invention to provide an electronic stimulation 16 device, for stimulating the atria from multiple sites, where the electrodes of the electronic 17 stimulation device can be inserted intravenously.
18 It is a further object of the present invention to provide an electronic stimulation 19 device, for stimulating the atria from multiple sites, where each electrode of the device has an independent generator.
21 It is a fixrther object of the present invention to provide an electronic stimulation 22 device for stimulating the atria from multiple sites, where each site is entrained separately 23 and quickly brought to the same phase.
It is a further object of the present invention to provide an electronic stimulation device for stimulating the atria from multiple sites, to sequence the sites to mimic a normal heart beat.
It is a further object of the present invention to determine cardiac capture by monitoring cardiac activity and noting when the baseline of such activity is off zero.
It is a further object of the present invention to decrease threshold rises due to a build up of fibrous tissue.
In accordance with one aspect of the present invention, there is provided an implantable cardiac stimulator to perform atrial defibrillation, the cardiac stimulator comprising: sensor adapted to sense the onset of atrial fibrillation; recorder adapted to record a baseline of cardiac activity; processor adapted to determining whether capture has occurred; and electrodes adapted to stimulate the atrium after the onset of atrial fibrillation has been sensed, wherein, in the event it is determined that capture has not occurred, the atrium is stimulated using a pre-capture stimulation protocol, wherein, in the event it is determined that capture has occurred, the atrium is stimulated using a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, the procedure being selected from the group consisting of: pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
In accordance with a second aspect of the present invention, there is provided an apparatus for electrical cardiac pacing comprising: a plurality of electrodes adapted to be disposed proximate atrial tissue; a sense amplifier connected to at least one of the plurality of electrodes to sense atrial fibrillation; a memory in electrical communication with the sense amplifier, for recording a baseline of cardiac activity; an electrical stimulation driver, connected to at least one of the plurality of electrodes, to stimulate atrial tissue; and processor circuitry programmed to determine status of pacing capture;
wherein, in the event that atrial fibrillation is sensed, the electrical stimulation driver uses a pre-capture stimulation protocol, wherein, in the event that capture status is determined, the electrical stimulation driver uses a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, and wherein the procedure is selected from the group consisting of: pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
The present invention accomplishes the above objectives by providing a cardiac pacemaker with a unique constellation of features and capabilities. In particular, a means for entraining multiple atrial sites is provided by the use of multiple electrodes. The multiple electrodes not only permit multi-site stimulation capability, but also multi-site sensing (including pdf measurement) capability, which, by triangulation, essentially provides the ability to determine the site(s) of any atrial ectopic focus. The 7a = ' .
multi-site stimulation capability inherently provides a system poised for more efficient entrainment and/or cardioconversion of the atria in the face of arrhythmia, fibrillation, etc. Combined with this multi-site stimulation/sensing capability is the means to execute trial-and-error testing and analysis to determine the best general stimulation protocol, to fine tune a given protocol, or to adjust a protocol in response to changes in the physiological/pathological status of the patient in general and/or the patient's heart in particular.
Incorporating the use of biphasic stimulation with the present invention provides the additional benefits of reducing cardiac inflammation damage, reducing or eliminating threshold rises due to the buildup of fibrous tissue and extending battery life of the electrodes.
7b 1 In addition, the ability to conduct trial-and-error testing, including the analysis of 2 the data derived therefrom, permits more thorough and more definitive determination of 3 the physiological status of the heart; this determination can practically approach a 4 moment-to-moment basis when analysis is automated by appropriate software for the purpose.
6 In sum, the present invention provides a cardiac pacemaker that has greater 7 functional capabilities for the patient's atria than current technologies allow. The greater 8 atrial "coverage" from the strategic placement of multiple electrodes permits faster 9 correction of atrial arrhythmia, fibrillation, etc. Similarly, the use of multi-site electrodes permits more accurate sensing, including the capability of locating the site(s) of any atrial 11 ectopic focus so as to better apply corrective stimulation procedures. In addition, the 12 ability to apply trial-and-error testing/analytical procedures permits quicker analysis and 13 correction of malfunctions of electrical conduction, cardiac contractility, rhythmicity, etc.
14 Thus, the present invention constitutes an advance in cardiac care procedures as they relate to atrial pacemakers. The end result for the patient is better treatment, and, hence, a better 16 prognosis from the better and faster treatment.
17 The method and apparatus relating to biphasic pacing comprises a first and second 18 stimulation phase, with each stimulation phase having a polarity, amplitude, shape, and 19 duration. In a preferred embodiment, the first and second phases have differing polarities.
In one alternative embodiment, the two phases are of differing amplitude. In a second 21 alternative embodiment, the two phases are of differing duration. In a third alternative 22 embodiment, the first phase is in a chopped wave form. In a fourth alternative 23 embodiment, the amplitude of the first phase is ramped. In a fifth alternative embodiment 1 the first phase is administered over 200 milliseconds after completion of a cardiac 2 beating/pumping cycle. In a preferred alternative embodiment, the first phase of 3 stimulation is an anodal pulse at maximum subthreshold amplitude for a long duration, 4 and the second phase of stimulation is a cathodal pulse of short duration and high amplitude. It is noted that the aforementioned alternative embodiments can be combined 6 in differing fashions. It is also noted that these alternative embodiments are intended to be 7 presented by way of example only, and are not limiting.
8 Enhanced myocardial function is obtained through the biphasic stimulation of the 9 present invention. The combination of cathodal with anodal pulses of either a stimulating or conditioning nature, preserves the improved conduction and contractility of anodal 11 stimulation while eliminating the drawback of increased stimulation threshold. The result 12 is a depolarization wave of increased propagation speed. This increased propagation speed 13 results in increased synchronization and reduced heterogenicity of myocardial 14 depolarization resulting in superior blood flow and contraction. Improved stimulation at a lower voltage level also results in: 1/ reduction in scar tissue buildup thereby reducing the 16 tendency of the capture threshold to rise; 2/ reduction in power consumption leading to 17 increased life for pacemaker batteries; and 3/ decreased potential for patient discomfort 18 due to stimulation of the phrenic or diaphragmatic plexus or due to intercostal muscle 19 pacing.
Brief Description of the Drawings 21 Figure 1 illustrates the location of leads and electrodes in relation to a human heart.
22 Figure 2 illustrates an alternative location of leads and electrodes in relation to a 23 human heart.
A Figure 2A illustrates a block diagram of the major functional components of the 2 implanted pacemaker.
3 Figure 3 is a schematic representation of leading anodal biphasic stimulation.
4 Figure 4 is a schematic representation of leading cathodal biphasic stimulation.
Figure 5 is a schematic representation of leading anodal stimulation of low level 6 and long duration, followed by conventional cathodal stimulation.
7 Figure 6 is a schematic representation of leading anodal stimulation of ramped low 8 level and long duration, followed by conventional cathodal stimulation.
9 Figure 7 is a schematic representation of leading anodal stimulation of low level and short duration, administered in series followed by conventional cathodal stimulation.
11 Figure 8 illustrates the practice of the present invention.
12 Description of the Preferred Embodiments 13 Electrical stimulation is delivered via lead(s) or electrode(s). These leads can be 14 epicardial (external surface of the heart) or endocardial (internal surface of the heart) or any combination of epicardial and endocardial. Leads are well known to those skilled in 16 the art. Lead systems can be unipolar or bipolar. A unipolar lead has one electrode on the 17 lead itself, the cathode. Current flows from the cathode, stimulates the heart, and returns 18 to the anode on the casing of the pulse generator to complete the circuit.
A bipolar lead 19 has two poles on the lead a short distance from each other at the distal end, and both electrodes lie within the heart.
21 Figure 1 illustrates a plan view of implantable electronic stimulation device 102 22 and its associated lead and electrode system, in conjunction with human heart 104. As 23 illustrated, the device includes right atrial appendage lead 106, right atrial septal lead 108, 1 first coronary sinus lead 110 and second coronary sinus lead 112. Each of these multiple 2 small electrodes can be inserted intravenously and includes an independent generator.
3 Figure 2 illustrates a plan view of implantable electronic stimulation device 102 4 illustrating an alternative location of leads and electrodes in relation to human heart 104.
As illustrated, the device includes right atrial appendage lead 106, right atrial septal lead 6 108, first coronary sinus lead 110, second coronary sinus lead 112 and left free wall lead 7 204. Each of these multiple small electrodes can be inserted intravenously and includes an 8 independent generator. Because of the use of independent generators, each electrode can 9 be timed differently. In a preferred embodiment, left free wall lead 204 is placed by piercing septum 206 and passing left free wall lead 204 through the septum to the left side 11 of the heart. The aforementioned placement of leads is for illustration purposes only, and 12 is not intended as a limitation. It is contemplated that multiple leads placed in a variety of 13 locations could be used.
14 Each site (area of lead placement) can be entrained separately, and then brought to the same phase. In a preferred embodiment each site is gradually brought to the same 16 phase; however, certain situations could require that each site is quickly brought to the 17 same phase. In an alternative embodiment, the sites can be sequenced to mimic a normal 18 heart beat. In addition to allowing multi-site stimulation capability, the sensing circuits of 19 each electrode also allow for multi-site sensing. Through triangulation the multi-site sensing provides a means for determining the site(s) of any atrial ectopic focus.
21 Referring to Figure 2A, a block diagram shows the major functional components 22 of the implanted pacemaker 102. Pacing/control circuitry 500, in conjunction with 23 microprocessor 501 detects the occurrence of tachycardia (and/or bradycardia) and in 1 response thereto controls the delivery of the various pacing therapies available via control 2 bus 512. The microprocessor 501 also detects the occurrence of atrial fibrillation.
3 Detection of atrial fibrillation may be accomplished by the microprocessor 501 using any 4 of the various detection methodologies known to the art. Generally, atrial fibrillation may be detected in response to an extended series of high rate atrial depolarizations. If greater 6 specificity for atrial fibrillation is desired, analysis of regularity of rate waveform 7 morphology may also be employed. Termination of atrial fibrillation may be detected in 8 response to a decrease in the rate of atrial depolarizations and/or an increase in their 9 regularity.
The operation of the microprocessor 501 is controlled by programming stored in a 11 read only memory 505 and in a random access memory 503. The operation of the device 12 may be altered by the physician by altering the programming stored in the memory 503, 13 using control and telemetry circuitry conventional in implantable stimulators.
14 Communication to and from the microprocessor 501, the memories 503, 505, and the control logic 500 is accomplished using an address/data bus 507.
16 The atrial sensing circuit 509 can be any conventional cardiac sense amplifier 17 circuits equivalent to any atrial cardiac sensing circuits employed in previous devices 18 known in the art.
19 The implanted pacemaker 102 has a switch matrix 516 that allows selective delivery of pacing pulses from the atrial pacing driver 514 to the electrodes.
The matrix 21 516 may be embodied as simply a collection of one or more FET and/or SCR
switches 22 activated under control of the pacing/control circuitry 500 to selectively pacing circuitry 23 516 to electrodes 106 and 108, or to electrodes 110 and 112, or other combinations of the 24 electrodes. Thus, atrial anti-tachycardia (or anti-bradycardia pacing) is performed using any combination of the deployed pacing electrodes.
1 In a preferred embodiment, stimulation is administered at threshold until capture 2 has occurred, at which time stimulation is administered at a subthreshold level. In 3 alternative embodiments, stimulation is: (1) initiated at threshold and remains at threshold;
4 (2) initiated subthreshold and remains subthreshold; (3) conventional prior to capture and then biphasic; (4) biphasic prior to capture and then conventional or (5) biphasic 6 throughout.
7 Threshold refers to the minimum voltage level (or pulse width using a fixed 8 voltage) which succeeds in stimulating (capturing) the myocardium. To capture is to 9 produce a driven beat because of the stimulus given. Thus, in the absence of the pulse, the beat would not have been produced. Pulses which do not capture are subthreshold, (even 11 though they may be shown to perturb the membrane potential somewhat, and transiently).
12 Subthreshold pulses thus may affect subsequent conduction, but not by the mechanism of 13 initiating a driven beat. Generally, to determine threshold, voltage (or pulse width) is 14 varied (upward or downward) until capture is gained or lost.
Conventional stimulation is well known to those skilled in the art and comprises 16 monophasic waveforms (cathodal or anodal) as well as multiphasic waveforms wherein 17 the nonstimulating pulses are of a minimal magnitude and are used, for example, to 18 dissipate a residual charge on an electrode.
19 Figures 3 through 7 depict a range of biphasic stimulation protocols. These protocols have been disclosed in United States Patent Application No.
08/699,552 to 21 Mower, which is herein incorporated by reference in its entirety.
22 Figure 3 depicts biphasic electrical stimulation wherein a first stimulation phase 23 comprising anodal stimulus 302 is administered having amplitude 304 and duration 306.
1 This first stimulation phase is immediately followed by a second stimulation phase 2 comprising cathodal stimulation 308 of equal intensity and duration.
3 Figure 4 depicts biphasic electrical stimulation wherein a first stimulation phase 4 comprising cathodal stimulation 402 having amplitude 404 and duration 406 is administered. This first stimulation phase is immediately followed by a second 6 stimulation phase comprising anodal stimulation 408 of equal intensity and duration.
7 Figure 5 depicts a preferred embodiment of biphasic stimulation wherein a first 8 stimulation phase, comprising low level, long duration anodal stimulation 502 having 9 amplitude 504 and duration 506, is administered. This first stimulation phase is immediately followed by a second stimulation phase comprising cathodal stimulation 508 11 of conventional intensity and duration. In differing alternative embodiments, anodal 12 stimulation 502 is: 1) at maximum subthreshold amplitude; 2) less than three volts; 3) of a 13 duration of approximately two to eight milliseconds; and/or 4) administered over 200 14 milliseconds post heart beat. Maximum subthreshold amplitude is defined for purposes of this application as the maximum stimulation amplitude that can be administered without 16 eliciting a contraction. In a preferred embodiment, anodal stimulation is approximately 17 two volts for approximately three milliseconds duration. In differing alternative 18 embodiments, cathodal stimulation 508 is: 1) of a short duration; 2) approximately 0.3 to 19 1.5 milliseconds; 3) of a high amplitude; 4) in the approximate range of three to twenty volts; and/or 5) of a duration less than 0.3 millisecond and at a voltage greater than twenty 21 volts. In a preferred embodiment, cathodal stimulation is approximately six volts 22 administered for approximately 0.4 millisecond. In the manner disclosed by these 23 embodiments, as well as those alterations and modifications which can become obvious 1 upon the reading of this specification, a maximum membrane potential without activation 2 is achieved in the first phase of stimulation.
3 Figure 6 depicts an alternative preferred embodiment of biphasic stimulation 4 wherein a first stimulation phase, comprising anodal stimulation 602, is administered over period 604 with rising intensity level 606. The ramp of rising intensity level 606 can be 6 linear or non-linear, and the slope can vary. This anodal stimulation is immediately 7 followed by a second stimulation phase comprising cathodal stimulation 608 of 8 conventional intensity and duration. In alternative embodiments, anodal stimulation 602:
9 (1) rises to a maximum subthreshold amplitude less than three volts; (2) is of a duration of approximately two to eight milliseconds; and/or (3) is administered over 200 milliseconds 11 post heart beat. In yet other alternative embodiments, cathodal stimulation 608 is: (1) of a 12 short duration; (2) approximately 0.3 to 1.5 milliseconds; (3) of a high amplitude; (4) in 13 the approximate range of three to twenty volts; and/or (5) of a duration less than 0.3 14 milliseconds and at a voltage greater than twenty volts. In the manner disclosed by these embodiments, as well as those alterations and modifications which can become obvious 16 upon the reading of this specification, a maximum membrane potential without activation 17 is achieved in the first phase of stimulation.
18 Figure 7 depicts biphasic electrical stimulation wherein a first stimulation phase, 19 comprising series 702 of anodal pulses, is administered at amplitude 704.
In one embodiment, rest period 706 is of equal duration to stimulation period 708, and is 21 administered at baseline amplitude. In an alternative embodiment, rest period 706 is of a 22 differing duration than stimulation period 708, and is administered at baseline amplitude.
23 Rest period 706 occurs after each stimulation period 708, with the exception that a second A stimulation phase, comprising cathodal stimulation 710 of conventional intensity and 2 duration, immediately follows the completion of series 702. In alternative embodiments:
3 (1) the total charge transferred through series 702 of anodal stimulation is at the maximum 4 subthreshold level; and/or (2) the first stimulation pulse of series 702 is administered over 200 milliseconds post heart beat. In yet other alternative embodiments, cathodal 6 stimulation 710 is: (1) of a short duration; (2) approximately 0.3 to 1.5 milliseconds; (3) of 7 a high amplitude; (4) in the approximate range of three to twenty volts, and/or (5) of a 8 duration less than 0.3 milliseconds and at a voltage greater than twenty volts.
9 Figure 8 illustrates the practice of the present invention. Sensing is used to determine the existence of atrial fibrillation 802. Sensing can be direct or indirect. For 11 example, direct sensing can be based on data from multiple atrial sensing electrodes. The 12 sensing electrodes sense the cardiac activity as depicted by electrical signals. For example, 13 as is known in the art, R-waves occur upon the depolarization of ventricular tissue and P-14 waves occur upon the depolarization of atrial tissue. By monitoring these electrical signals the control/timing circuit of the ICD can determine the rate and regularity of the patient's 16 heart beat, and thereby determine whether the heart is undergoing arrhythmia. This 17 determination can be made by determining the rate of the sensed R-waves and/or P-waves 18 and comparing this determined rate against various reference rates.
19 Direct sensing can be based upon varying criteria; such as, but not limited to, primary rate, sudden onset, and stability. The sole criteria of a primary rate sensor is the 21 heart rate. When applying the primary rate criteria, if the heart rate should exceed a 22 predefined level, then treatment is begun. Sensing electronics set to sudden onset criteria 23 ignore those changes which occur slowly, and initiate treatment when there is a sudden 1 change such as immediate paroxysmal arrhythmia. This type of criteria would thus 2 discriminate against sinus tachycardia. Stability of rate can also be an important criteria.
3 For example, treatment with a ventricular device would not be warranted for a fast rate 4 that varies, here treatment with an atrial device would be indicated.
In alternative embodiments, sensing can be indirect. Indirect sensing can be based 6 on any of various functional parameters such as arterial blood pressure, rate of the 7 electrocardiogram deflections or the probability density function (pdf) of the 8 electrocardiogram. While it has been known in the art to apply pdf to the global 9 electrocardiogram and/or to the R wave, it has been unexpectedly discovered that pdf of the baseline is also indicated for the determination of atrial abnormalities.
Here, the 11 electrodes are specific to the atrium and data related to the R wave is canceled out. Thus, 12 whether or not to administer treatment can also be affected by pdf monitoring of the time 13 the signal spends around the baseline.
14 Lastly, to determine whether an arrhythmia comes from the atria or the ventricles, a test impulse(s) can be given to one chamber to see if capture occurs and perturbs the 16 rhythm. For example, in a ventricular rhythm, an atrial test impulse can capture the 17 atrium, but the ventricular rhythm will continue unchanged afterwards. In an atrial 18 rhythm, (or Sinus rhythm), if the atrial test pulse captures, the timing of all subsequent 19 beats is changed. To determine if a pulse captures, the baseline immediately after the beat can be examined to determine if it is different from zero (or from a baseline template). If 21 so, the beat can be inferred to have captured. In addition, the pdf pattern of the rhythm can 22 be shown to have changed, inferring capture.
23 Thus, in a preferred embodiment, sensing electronics are based upon multiple 1 criteria. In addition, the present invention envisions devices working in more than one 2 chamber such that appropriate treatment can be administered to either the atrium or the 3 ventricle in response to sensing electronics based upon a variety of criteria, including those 4 described above as well as other criteria known to those skilled in the art.
If atrial fibrillation occurs, a baseline of cardiac activity or a template can be 6 recorded 804. The template can be based on parameters such as electrocardiogram data, 7 mechanical motion and/or probability density function data. In an alternative embodiment, 8 the template is established after capture has occurred.
9 Pacing is initiated 806. In a preferred embodiment, stimulation is administered at threshold until capture has occurred, at which time stimulation is administered at a 11 subthreshold level. In alternative embodiments, stimulation is: (1) initiated at threshold 12 and remains at threshold; (2) initiated subthreshold and remains subthreshold; (3) 13 conventional prior to capture and then biphasic; (4) biphasic prior to capture and then 14 conventional or (5) biphasic throughout.
The atrium is monitored throughout this initial pacing period to determine the 16 status of capture 808. Capture can be determined by multiple means. First, capture or the 17 loss thereof, can be determined by monitoring cardiac rhythm. Loss of capture can result 18 in a change in timing of the heart beat.
19 Second, capture or the loss thereof, can be determined through monitoring the previously described template. Where the template is established pre-stimulation, a 21 change in the baseline signifies capture. Where the template is established after capture 22 has occurred, a change in the template characteristics signifies loss of capture. The 23 templates can be established and/or updated at any time.
I Once capture occurs the stitnulntion protocol of the eatrained sites is adjusted 8]Q.
2 In a first embodiment, the stimulation rates of the entrained sites are slowed 3 siraultaneously, and then stopped. In a second emboditnent, the spread of conduction is 4 slowed. In a third embodiment, the stimulation speed is increased and stimulation is then stopped. In addition to adjusting stimulation .rates upon the occurrence of capture, the 6 stimulation protocol can also be adjusted such that (1) if stimWation of a conventional 7 nature was administered prior to capture, biphasic stimulation is administered post-8 capture; (2) if bipbasic stimulation was administered prior to capture, conventional 9 stimulation is administered post-capture or (3) if biphasic stimulatioja was administered prior to capture, biphasic stimulation continues to be administered post-capture.
11 Having thus described the basic concept of the invention, it will be readily agparent 12 to those skilled in the art that the foregoing detailed disclosure is intended to be presented 13 by way of example only, and is not limiting. Various alterations, improvements and 14 modifications will occur and are intended to those skilled in the art, but are not expressly stated herein. These modifications, alterations and improvements are intended to be 16 suggested hereby, and. within the scope of the invention. Futher, the pacing pulses 17 described in this specification are well within the capabilities of existing pacemaker l 8 electronics with appropriate programming. Accordingly, the invention is limited only by 19 the following claims.
Claims (44)
1. An implantable cardiac stimulator to perform atrial defibrillation, the cardiac stimulator comprising:
sensor adapted to sense the onset of atrial fibrillation;
recorder adapted to record a baseline of cardiac activity;
processor adapted to determining whether capture has occurred; and electrodes adapted to stimulate the atrium after the onset of atrial fibrillation has been sensed, wherein, in the event it is determined that capture has not occurred, the atrium is stimulated using a pre-capture stimulation protocol, wherein, in the event it is determined that capture has occurred, the atrium is stimulated using a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, the procedure being selected from the group consisting of:
pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
sensor adapted to sense the onset of atrial fibrillation;
recorder adapted to record a baseline of cardiac activity;
processor adapted to determining whether capture has occurred; and electrodes adapted to stimulate the atrium after the onset of atrial fibrillation has been sensed, wherein, in the event it is determined that capture has not occurred, the atrium is stimulated using a pre-capture stimulation protocol, wherein, in the event it is determined that capture has occurred, the atrium is stimulated using a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, the procedure being selected from the group consisting of:
pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
2. The implantable cardiac stimulator of claim 1, wherein the procedure utilizes biphasic stimulation pre-capture with biphasic stimulation post-capture.
3. The implantable cardiac stimulator of claim 2, where at least two of the electrodes are adapted to be inserted intravenously into a patient, and at least two of the electrodes are adapted to be placed in conjunction with cardiac tissue.
4. The implantable cardiac stimulator of claim 3, wherein at least one of the electrodes is adapted to be located in the right atrial appendage, at least one of the electrodes is adapted to be located in the right atrial septum, and at least one of the electrodes is adapted to be located in the coronary sinus.
5. The implantable cardiac stimulator of claim 4, wherein at least one of the electrodes is adapted to be located in the left free wall.
6. The implantable cardiac stimulator of claim 3, wherein each of the electrodes has an independent generator.
7. The implantable cardiac stimulator of claim 3, wherein the stimulation of the electrodes is sequenced so as to mimic a normal heart beat.
8. The implantable cardiac stimulator of claim 2, wherein the processor determines status of capture by monitoring for changes in the baseline of cardiac activity established by the recorder.
9. The implantable cardiac stimulator of claim 2, wherein the baseline of cardiac activity comprises a template of parameters selected from the group consisting of: electrocardiogram data, mechanical motion, and probability density function data.
10. The implantable cardiac stimulator of claim 2, wherein biphasic stimulation comprises:
defining a first stimulation phase with a first phase polarity, a first phase amplitude, a first phase shape and a first phase duration;
defining a second stimulation phase with a polarity opposite to the first phase polarity, a second phase amplitude, a second phase shape and a second phase duration; and applying the first stimulation phase and the second stimulation phase in sequence to cardiac tissue.
defining a first stimulation phase with a first phase polarity, a first phase amplitude, a first phase shape and a first phase duration;
defining a second stimulation phase with a polarity opposite to the first phase polarity, a second phase amplitude, a second phase shape and a second phase duration; and applying the first stimulation phase and the second stimulation phase in sequence to cardiac tissue.
11. The implantable cardiac stimulator of claim 10, wherein the first phase polarity is positive.
12. The implantable cardiac stimulator of claim 10, wherein the first phase amplitude is less than the second phase amplitude.
13. The implantable cardiac stimulator of claim 10, wherein the first phase amplitude is ramped from a baseline value to a second value.
14. The implantable cardiac stimulator of claim 13, wherein the second value is equal to the second phase amplitude.
15. The implantable cardiac stimulator of claim 13, wherein the second value is at a maximum subthreshold amplitude.
16. The implantable cardiac stimulator of claim 15, wherein the maximum subthreshold amplitude is about 0.5 to 3.5 volts.
17. The implantable cardiac stimulator of claim 13, wherein the first phase duration is at least as long as the second phase duration.
18. The implantable cardiac stimulator of claim 13, wherein the first phase duration is about one to nine milliseconds.
19. The implantable cardiac stimulator of claim 13, wherein the second phase duration is about 0.2 to 0.9 milliseconds.
20. The implantable cardiac stimulator of claim 13, wherein the second phase amplitude is about two volts to twenty volts.
21. The implantable cardiac stimulator of claim 13, wherein the second phase duration is less than 0.3 milliseconds and the second phase amplitude is greater than 20 volts.
22. The implantable cardiac stimulator of claim 10, wherein the first stimulation phase further comprises a series of stimulating pulses of a predetermined amplitude, polarity and duration.
23. The implantable cardiac stimulator of claim 22, wherein the first stimulation phase further comprises a series of rest periods.
24. The implantable cardiac stimulator of claim 23, wherein applying the first stimulation phase further comprises applying a rest period of a baseline amplitude after at least one stimulating pulse.
25. The implantable cardiac stimulator of claim 24, wherein the rest period is of equal duration to the stimulating pulse.
26. The implantable cardiac stimulator of claim 10, wherein the first phase amplitude is at a maximum subthreshold amplitude.
27. The implantable cardiac stimulator of claim 26, wherein the maximum subthreshold amplitude is about 0.5 to 3.5 volts.
28. The implantable cardiac stimulator of claim 10, wherein the first phase duration is at least as long as the second phase duration.
29. The implantable cardiac stimulator of claim 10, wherein the first phase duration is about one to nine milliseconds.
30. The implantable cardiac stimulator of claim 10, wherein the second phase duration is about 0.2 to 0.9 milliseconds.
31. The implantable cardiac stimulator of claim 10, wherein the second phase amplitude is about two volts to twenty volts.
32. The implantable cardiac stimulator of claim 10, wherein the second phase duration is less than 0.3 milliseconds and the second phase amplitude is greater than 20 volts.
33. The implantable cardiac stimulator of claim 10, wherein the first stimulation phase is initiated greater than 200 milliseconds after heart beat.
34. The implantable cardiac stimulator of claim 10, wherein the first stimulation phase comprises anodal stimulation.
35. The implantable cardiac stimulator of claim 2, wherein the sensor senses atrial fibrillation by monitoring parameters selected from the group consisting of: arterial blood pressure, rate of electrocardiogram deflections, and probability density function of the electrocardiogram.
36. The implantable cardiac stimulator of claim 2, further comprising:
sensing circuits, each of the sensing circuits being connected to a respective one of the electrodes and being adapted to provide sensing data concerning the site of one or more atrial ectopic foci.
sensing circuits, each of the sensing circuits being connected to a respective one of the electrodes and being adapted to provide sensing data concerning the site of one or more atrial ectopic foci.
37. The implantable cardiac stimulator of claim 36, wherein the processor is connected to receive the sensing data from the sensing circuits and determines the site of one or more atrial ectopic foci by triangulating the sensing data.
38. An apparatus for electrical cardiac pacing comprising:
a plurality of electrodes adapted to be disposed proximate atrial tissue;
a sense amplifier connected to at least one of the plurality of electrodes to sense atrial fibrillation;
a memory in electrical communication with the sense amplifier, for recording a baseline of cardiac activity;
an electrical stimulation driver, connected to at least one of the plurality of electrodes, to stimulate atrial tissue; and processor circuitry programmed to determine status of pacing capture;
wherein, in the event that atrial fibrillation is sensed, the electrical stimulation driver uses a pre-capture stimulation protocol, wherein, in the event that capture status is determined, the electrical stimulation driver uses a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, and wherein the procedure is selected from the group consisting of: pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
a plurality of electrodes adapted to be disposed proximate atrial tissue;
a sense amplifier connected to at least one of the plurality of electrodes to sense atrial fibrillation;
a memory in electrical communication with the sense amplifier, for recording a baseline of cardiac activity;
an electrical stimulation driver, connected to at least one of the plurality of electrodes, to stimulate atrial tissue; and processor circuitry programmed to determine status of pacing capture;
wherein, in the event that atrial fibrillation is sensed, the electrical stimulation driver uses a pre-capture stimulation protocol, wherein, in the event that capture status is determined, the electrical stimulation driver uses a post-capture stimulation protocol, and wherein the pre-capture stimulation protocol and the post-capture stimulation protocol comprise a procedure, and wherein the procedure is selected from the group consisting of: pre-capture stimulation at threshold with post-capture stimulation at threshold, pre-capture stimulation subthreshold with post-capture stimulation subthreshold, and pre-capture stimulation at threshold with post-capture stimulation subthreshold.
39. The apparatus for electrical cardiac pacing of claim 38, wherein the procedure uses biphasic stimulation post-capture.
40. The apparatus for electrical cardiac pacing of claim 39, wherein the biphasic stimulation has a first phase that comprises anodal stimulation.
41. The apparatus for electrical cardiac pacing of claim 38, wherein the procedure uses biphasic stimulation pre-capture.
42. The apparatus for electrical cardiac pacing of claim 41, wherein the biphasic stimulation has a first phase that comprises anodal stimulation.
43. The apparatus for electrical cardiac pacing of claim 38, wherein the procedure uses biphasic stimulation pre-capture with biphasic stimulation post-capture.
44. The apparatus for electrical cardiac pacing of claim 43, wherein the biphasic stimulation has a first phase that comprises anodal stimulation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/228,262 | 1999-01-11 | ||
| US09/228,262 US6178351B1 (en) | 1996-08-19 | 1999-01-11 | Atrial sensing and multiple site stimulation as intervention means for atrial fibrillation |
| PCT/US2000/000777 WO2000041765A1 (en) | 1999-01-11 | 2000-01-11 | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2359285A1 CA2359285A1 (en) | 2000-07-20 |
| CA2359285C true CA2359285C (en) | 2008-08-19 |
Family
ID=22856450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002359285A Expired - Fee Related CA2359285C (en) | 1999-01-11 | 2000-01-11 | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6178351B1 (en) |
| EP (1) | EP1150744B1 (en) |
| JP (1) | JP2002534232A (en) |
| KR (1) | KR100517078B1 (en) |
| AP (1) | AP2001002229A0 (en) |
| AT (1) | ATE288300T1 (en) |
| AU (1) | AU769602B2 (en) |
| BR (1) | BR0007477A (en) |
| CA (1) | CA2359285C (en) |
| CZ (1) | CZ20012532A3 (en) |
| DE (1) | DE60017873T2 (en) |
| EA (1) | EA005662B1 (en) |
| EE (1) | EE200100365A (en) |
| ES (1) | ES2237412T3 (en) |
| HU (1) | HUP0105060A2 (en) |
| IL (1) | IL144260A (en) |
| MX (1) | MXPA01007040A (en) |
| NO (1) | NO20013446L (en) |
| NZ (1) | NZ513225A (en) |
| PL (1) | PL366287A1 (en) |
| PT (1) | PT1150744E (en) |
| SK (1) | SK9952001A3 (en) |
| TR (1) | TR200102710T2 (en) |
| WO (1) | WO2000041765A1 (en) |
| ZA (1) | ZA200105918B (en) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6343232B1 (en) | 1966-08-19 | 2002-01-29 | Mower Chf Treatment Irrevocable Trust | Augmentation of muscle contractility by biphasic stimulation |
| US8825152B2 (en) * | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
| US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
| US7167748B2 (en) * | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
| US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
| US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
| US6341235B1 (en) | 1996-08-19 | 2002-01-22 | Mower Chf Treatment Irrevocable Trust | Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool |
| US7840264B1 (en) | 1996-08-19 | 2010-11-23 | Mr3 Medical, Llc | System and method for breaking reentry circuits by cooling cardiac tissue |
| US7908003B1 (en) | 1996-08-19 | 2011-03-15 | Mr3 Medical Llc | System and method for treating ischemia by improving cardiac efficiency |
| US8447399B2 (en) * | 1996-08-19 | 2013-05-21 | Mr3 Medical, Llc | System and method for managing detrimental cardiac remodeling |
| US6295470B1 (en) * | 1996-08-19 | 2001-09-25 | The Mower Family Chf Treatment Irrevocable Trust | Antitachycardial pacing |
| US6337995B1 (en) | 1996-08-19 | 2002-01-08 | Mower Chf Treatment Irrevocable Trust | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation |
| US6411847B1 (en) | 1996-08-19 | 2002-06-25 | Morton M. Mower | Apparatus for applying cyclic pacing at an average rate just above the intrinsic heart rate |
| AU759719B2 (en) * | 1999-02-04 | 2003-04-17 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| US6411845B1 (en) | 1999-03-04 | 2002-06-25 | Mower Chf Treatment Irrevocable Trust | System for multiple site biphasic stimulation to revert ventricular arrhythmias |
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8019421B2 (en) * | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
| US8666495B2 (en) * | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US8700161B2 (en) * | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
| WO2006073671A1 (en) | 2004-12-09 | 2006-07-13 | Impulse Dynamics Nv | Protein activity modification |
| US20040249421A1 (en) * | 2000-09-13 | 2004-12-09 | Impulse Dynamics Nv | Blood glucose level control |
| US8346363B2 (en) * | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
| US6993385B1 (en) * | 1999-10-25 | 2006-01-31 | Impulse Dynamics N.V. | Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof |
| WO2001030445A1 (en) | 1999-10-25 | 2001-05-03 | Impulse Dynamics N.V. | Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof |
| AU2001249877A1 (en) | 2000-04-13 | 2001-10-30 | Uab Research Foundation | Inter-atrial septum electrode for atrial defibrillation |
| EP1584351A1 (en) | 2000-11-22 | 2005-10-12 | Medtronic, Inc. | Apparatus for detecting and treating ventricular arrhythmia |
| US6622040B2 (en) | 2000-12-15 | 2003-09-16 | Cardiac Pacemakers, Inc. | Automatic selection of stimulation chamber for ventricular resynchronization therapy |
| US7181285B2 (en) | 2000-12-26 | 2007-02-20 | Cardiac Pacemakers, Inc. | Expert system and method |
| US7130682B2 (en) | 2000-12-26 | 2006-10-31 | Cardiac Pacemakers, Inc. | Pacing and sensing vectors |
| EP1392394A4 (en) * | 2001-06-04 | 2005-05-18 | Albert Einstein Healthcare Network | Cardiac stimulating apparatus having a blood clot filter and atrial pacer |
| US8116885B2 (en) * | 2001-10-15 | 2012-02-14 | Xiangsheng Zheng | Bachmann's bundle electrode for atrial defibrillation |
| US6907286B1 (en) | 2001-10-19 | 2005-06-14 | Pacesetter, Inc. | Anti-tachycardia pacing methods and devices |
| US6876880B2 (en) * | 2001-12-20 | 2005-04-05 | Medtronic, Inc. | Automated reapplication of atrial pacing therapies |
| US7983759B2 (en) | 2002-12-18 | 2011-07-19 | Cardiac Pacemakers, Inc. | Advanced patient management for reporting multiple health-related parameters |
| US7043305B2 (en) | 2002-03-06 | 2006-05-09 | Cardiac Pacemakers, Inc. | Method and apparatus for establishing context among events and optimizing implanted medical device performance |
| US20040122294A1 (en) | 2002-12-18 | 2004-06-24 | John Hatlestad | Advanced patient management with environmental data |
| US7110815B2 (en) * | 2002-05-06 | 2006-09-19 | Cardiac Pacemakers, Inc. | System and method for providing temporary stimulation therapy to optimize chronic electrical performance for electrodes used in conjunction with a cardiac rhythm management system |
| US7321794B2 (en) * | 2002-11-15 | 2008-01-22 | Advanced Bionics Corporation | Method and system for treating atrial fibrillation |
| US7136707B2 (en) | 2003-01-21 | 2006-11-14 | Cardiac Pacemakers, Inc. | Recordable macros for pacemaker follow-up |
| DE202004021638U1 (en) | 2003-02-10 | 2009-12-31 | N-Trig Ltd. | Touch detection for a digitizer |
| CN1787850B (en) * | 2003-03-10 | 2015-12-16 | 脉冲动力公司 | For transmitting the signal of telecommunication to revise the apparatus and method of gene expression in heart tissue |
| US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
| US8027721B2 (en) | 2003-03-24 | 2011-09-27 | Physio-Control, Inc. | Balanced charge waveform for transcutaneous pacing |
| US7136700B1 (en) * | 2003-06-02 | 2006-11-14 | Pacesetter, Inc. | System and method for delivering post-atrial arrhythmia therapy |
| US8792985B2 (en) * | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US20050055057A1 (en) * | 2003-09-05 | 2005-03-10 | Mirowski Famliy Ventures, L.L.C. | Method and apparatus for providing ipselateral therapy |
| US20050107833A1 (en) * | 2003-11-13 | 2005-05-19 | Freeman Gary A. | Multi-path transthoracic defibrillation and cardioversion |
| US7769450B2 (en) * | 2004-11-18 | 2010-08-03 | Cardiac Pacemakers, Inc. | Cardiac rhythm management device with neural sensor |
| US8548583B2 (en) * | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
| US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
| US8352031B2 (en) * | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
| US7136702B2 (en) * | 2004-03-19 | 2006-11-14 | Medtronic, Inc. | Method and apparatus for delivering multi-directional defibrillation waveforms |
| US8175702B2 (en) | 2004-11-04 | 2012-05-08 | The Washington University | Method for low-voltage termination of cardiac arrhythmias by effectively unpinning anatomical reentries |
| EP1812108B1 (en) * | 2004-11-18 | 2010-05-19 | Cardiac Pacemakers, Inc. | Cardiac rhythm management device with neural sensor |
| US7289847B1 (en) | 2005-01-18 | 2007-10-30 | Pacesetter, Inc. | Implantable cardiac device and method of treating atrial fibrillation |
| US20060159587A1 (en) * | 2005-01-19 | 2006-07-20 | Beckman Coulter, Inc. | Automated clinical analyzer with dual level storage and access |
| US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
| US8244371B2 (en) * | 2005-03-18 | 2012-08-14 | Metacure Limited | Pancreas lead |
| US20090234417A1 (en) * | 2005-11-10 | 2009-09-17 | Electrocore, Inc. | Methods And Apparatus For The Treatment Of Metabolic Disorders |
| US20070106337A1 (en) * | 2005-11-10 | 2007-05-10 | Electrocore, Inc. | Methods And Apparatus For Treating Disorders Through Neurological And/Or Muscular Intervention |
| CA2673971C (en) | 2006-11-13 | 2016-07-19 | Washington University Of St. Louis | Cardiac pacing using the inferior nodal extension |
| US8874208B2 (en) | 2007-12-11 | 2014-10-28 | The Washington University | Methods and devices for three-stage ventricular therapy |
| US8560066B2 (en) | 2007-12-11 | 2013-10-15 | Washington University | Method and device for three-stage atrial cardioversion therapy |
| EP2231263B1 (en) * | 2007-12-11 | 2016-03-16 | Washington University in St. Louis | Device for low-energy termination of atrial tachyarrhythmias |
| US7890182B2 (en) | 2008-05-15 | 2011-02-15 | Boston Scientific Neuromodulation Corporation | Current steering for an implantable stimulator device involving fractionalized stimulation pulses |
| US7996085B2 (en) * | 2008-11-12 | 2011-08-09 | Biosense Webster, Inc. | Isolation of sensing circuit from pace generator |
| US8644927B2 (en) * | 2009-04-21 | 2014-02-04 | Incube Labs, Llc | Apparatus and method for the detection and treatment of atrial fibrillation |
| WO2011092710A2 (en) | 2010-02-01 | 2011-08-04 | Metacure Limited | Gastrointestinal electrical therapy |
| US8473051B1 (en) | 2010-12-29 | 2013-06-25 | Cardialen, Inc. | Low-energy atrial cardioversion therapy with controllable pulse-shaped waveforms |
| US10905884B2 (en) | 2012-07-20 | 2021-02-02 | Cardialen, Inc. | Multi-stage atrial cardioversion therapy leads |
| US8868178B2 (en) | 2012-12-11 | 2014-10-21 | Galvani, Ltd. | Arrhythmia electrotherapy device and method with provisions for mitigating patient discomfort |
| US10940318B2 (en) | 2014-06-17 | 2021-03-09 | Morton M. Mower | Method and apparatus for electrical current therapy of biological tissue |
| RU2609276C2 (en) * | 2015-11-06 | 2017-02-01 | Общество с ограниченной ответственностью "Лаборатория медицинской электроники "Биоток" | Method for formation of pulsed electric field for painless endocardial cardioversion |
| JP6645914B2 (en) * | 2016-06-15 | 2020-02-14 | 日本電信電話株式会社 | Wearable device |
| JP6646177B2 (en) * | 2019-07-25 | 2020-02-14 | 日本電信電話株式会社 | Wearable device |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1459397A (en) | 1973-03-22 | 1976-12-22 | Biopulse Co Ltd | Apparatus for treating organisms by applying an electrical signal thereto |
| US3924641A (en) | 1974-08-19 | 1975-12-09 | Axotronics Inc | Bi-phasic current stimulation system |
| US4343312A (en) | 1979-04-16 | 1982-08-10 | Vitafin N.V. | Pacemaker output circuit |
| US4402322A (en) | 1981-03-25 | 1983-09-06 | Medtronic, Inc. | Pacer output circuit |
| DE3207006A1 (en) | 1982-02-26 | 1983-09-08 | Siemens AG, 1000 Berlin und 8000 München | AV SEQUENTIAL HEART PACEMAKER |
| US4498478A (en) | 1982-09-13 | 1985-02-12 | Medtronic, Inc. | Apparatus for reducing polarization potentials in a pacemaker |
| DE3246266A1 (en) | 1982-12-14 | 1984-06-14 | Siemens AG, 1000 Berlin und 8000 München | METHOD / DEVICE FOR DISINFECTING WATER PATHS IN MEDICAL, IN PARTICULAR DENTAL, MEDICAL DEVICES |
| US4539991A (en) | 1983-02-11 | 1985-09-10 | Vitafin N.V. | Dual chamber pacemaker |
| US4569350A (en) | 1984-12-05 | 1986-02-11 | Cordis Corporation | System for detecting pacer mediated tachycardia |
| US5111811A (en) | 1985-06-20 | 1992-05-12 | Medtronic, Inc. | Cardioversion and defibrillation lead system with electrode extension into the coronary sinus and great vein |
| US4903700A (en) | 1986-08-01 | 1990-02-27 | Telectronics N.V. | Pacing pulse compensation |
| US5163429A (en) | 1987-10-06 | 1992-11-17 | Leonard Bloom | Hemodynamically responsive system for treating a malfunctioning heart |
| US5027815A (en) | 1987-11-25 | 1991-07-02 | Medtronic, Inc. | Dual chamber pacemaker with adaptive atrial escape interval |
| US4940054A (en) | 1988-04-29 | 1990-07-10 | Telectronics N.V. | Apparatus and method for controlling multiple sensitivities in arrhythmia control system including post therapy packing delay |
| US4944298A (en) | 1989-05-23 | 1990-07-31 | Siemens-Pacesetter, Inc. | Atrial rate based programmable pacemaker with automatic mode switching means |
| ATE143280T1 (en) | 1990-12-18 | 1996-10-15 | Ventritex Inc | DEVICE FOR PRODUCING CONFIGURABLE TWO-PHASE DEFLAMATION WAVEFORMS |
| EP0594620A4 (en) | 1991-07-15 | 1994-11-02 | Zmd Corp | Method and apparatus for transcutaneous cardiac pacing. |
| US5213098A (en) | 1991-07-26 | 1993-05-25 | Medtronic, Inc. | Post-extrasystolic potentiation stimulation with physiologic sensor feedback |
| US5193535A (en) | 1991-08-27 | 1993-03-16 | Medtronic, Inc. | Method and apparatus for discrimination of ventricular tachycardia from ventricular fibrillation and for treatment thereof |
| US5215083A (en) | 1991-10-07 | 1993-06-01 | Telectronics Pacing Systems, Inc. | Apparatus and method for arrhythmia induction in arrhythmia control system |
| US5181511A (en) | 1991-10-21 | 1993-01-26 | Telectronics Pacing Systems, Inc. | Apparatus and method for antitachycardia pacing using a virtual electrode |
| US5224475A (en) | 1991-11-20 | 1993-07-06 | Medtronic, Inc. | Method and apparatus for termination of ventricular tachycardia and ventricular fibrillation |
| US5534015A (en) | 1992-02-18 | 1996-07-09 | Angeion Corporation | Method and apparatus for generating biphasic waveforms in an implantable defibrillator |
| US5334220A (en) | 1992-11-13 | 1994-08-02 | Siemens Pacesetter, Inc. | Dual-chamber implantable pacemaker having an adaptive AV interval that prevents ventricular fusion beats and method of operating same |
| US5391185A (en) | 1993-02-22 | 1995-02-21 | Angeion Corporation | Atrial cardioverter with ventricular protection |
| US5411547A (en) | 1993-08-09 | 1995-05-02 | Pacesetter, Inc. | Implantable cardioversion-defibrillation patch electrodes having means for passive multiplexing of discharge pulses |
| US5421830A (en) | 1993-08-27 | 1995-06-06 | Pacesetter, Inc. | Programming system having means for recording and analyzing a patient's cardiac signal |
| FR2718036B1 (en) | 1994-04-05 | 1996-08-30 | Ela Medical Sa | Method for controlling a triple atrial pacemaker of the triple chamber type. |
| US5562708A (en) | 1994-04-21 | 1996-10-08 | Medtronic, Inc. | Method and apparatus for treatment of atrial fibrillation |
| US5735876A (en) * | 1994-05-31 | 1998-04-07 | Galvani Ltd. | Electrical cardiac output forcing method and apparatus for an atrial defibrillator |
| US5601615A (en) * | 1994-08-16 | 1997-02-11 | Medtronic, Inc. | Atrial and ventricular capture detection and threshold-seeking pacemaker |
| US5522858A (en) | 1994-10-26 | 1996-06-04 | Vitatron Medical, B.V. | Pacemaker with improved reaction to stable first degree atrio-ventricular block |
| US5480413A (en) | 1994-11-30 | 1996-01-02 | Telectronics Pacing Systems, Inc. | Apparatus and method for stabilizing the ventricular rate of a heart during atrial fibrillation |
| US5601608A (en) | 1995-02-02 | 1997-02-11 | Pacesetter, Inc. | Methods and apparatus for applying charge-balanced antiarrhythmia shocks |
| SE9500620D0 (en) | 1995-02-20 | 1995-02-20 | Pacesetter Ab | Cardiac stimulation device |
| US5620471A (en) | 1995-06-16 | 1997-04-15 | Pacesetter, Inc. | System and method for discriminating between atrial and ventricular arrhythmias and for applying cardiac therapy therefor |
| US6317631B1 (en) | 1996-01-08 | 2001-11-13 | Impulse Dynamics N.V. | Controlling heart performance using a non-excitatory electric field |
| US5713929A (en) | 1996-05-03 | 1998-02-03 | Medtronic, Inc. | Arrhythmia and fibrillation prevention pacemaker using ratchet up and decay modes of operation |
| US5800465A (en) | 1996-06-18 | 1998-09-01 | Medtronic, Inc. | System and method for multisite steering of cardiac stimuli |
| US5871506A (en) | 1996-08-19 | 1999-02-16 | Mower; Morton M. | Augmentation of electrical conduction and contractility by biphasic cardiac pacing |
| US5814079A (en) | 1996-10-04 | 1998-09-29 | Medtronic, Inc. | Cardiac arrhythmia management by application of adnodal stimulation for hyperpolarization of myocardial cells |
| US5855592A (en) * | 1997-04-24 | 1999-01-05 | Ep Technologies, Inc. | Systems and methods for multi-site cardiac defibrillation using multiple electrode structures |
| FR2763247B1 (en) | 1997-05-16 | 2000-02-18 | Ela Medical Sa | ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR A CARDIAC STIMULATOR, DEFIBRILLATOR AND / OR CARDIOVERTER FOR REDUCING ARRHYTHMIA EPISODES, ESPECIALLY ATRIAL ARRHYTHMIA |
| US5855594A (en) * | 1997-08-08 | 1999-01-05 | Cardiac Pacemakers, Inc. | Self-calibration system for capture verification in pacing devices |
-
1999
- 1999-01-11 US US09/228,262 patent/US6178351B1/en not_active Expired - Lifetime
-
2000
- 2000-01-11 ES ES00911579T patent/ES2237412T3/en not_active Expired - Lifetime
- 2000-01-11 KR KR10-2001-7008799A patent/KR100517078B1/en not_active IP Right Cessation
- 2000-01-11 DE DE60017873T patent/DE60017873T2/en not_active Expired - Lifetime
- 2000-01-11 SK SK995-2001A patent/SK9952001A3/en unknown
- 2000-01-11 MX MXPA01007040A patent/MXPA01007040A/en not_active IP Right Cessation
- 2000-01-11 AU AU33458/00A patent/AU769602B2/en not_active Ceased
- 2000-01-11 PT PT00911579T patent/PT1150744E/en unknown
- 2000-01-11 CA CA002359285A patent/CA2359285C/en not_active Expired - Fee Related
- 2000-01-11 HU HU0105060A patent/HUP0105060A2/en unknown
- 2000-01-11 BR BR0007477-2A patent/BR0007477A/en not_active Application Discontinuation
- 2000-01-11 EP EP00911579A patent/EP1150744B1/en not_active Expired - Lifetime
- 2000-01-11 AP APAP/P/2001/002229A patent/AP2001002229A0/en unknown
- 2000-01-11 TR TR2001/02710T patent/TR200102710T2/en unknown
- 2000-01-11 WO PCT/US2000/000777 patent/WO2000041765A1/en active IP Right Grant
- 2000-01-11 PL PL00366287A patent/PL366287A1/en not_active Application Discontinuation
- 2000-01-11 IL IL144260A patent/IL144260A/en not_active IP Right Cessation
- 2000-01-11 EA EA200100763A patent/EA005662B1/en not_active IP Right Cessation
- 2000-01-11 JP JP2000593373A patent/JP2002534232A/en active Pending
- 2000-01-11 CZ CZ20012532A patent/CZ20012532A3/en unknown
- 2000-01-11 NZ NZ513225A patent/NZ513225A/en unknown
- 2000-01-11 EE EEP200100365A patent/EE200100365A/en unknown
- 2000-01-11 AT AT00911579T patent/ATE288300T1/en not_active IP Right Cessation
-
2001
- 2001-07-11 NO NO20013446A patent/NO20013446L/en not_active Application Discontinuation
- 2001-07-18 ZA ZA200105918A patent/ZA200105918B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU769602B2 (en) | 2004-01-29 |
| PL366287A1 (en) | 2005-01-24 |
| KR20010092468A (en) | 2001-10-26 |
| EP1150744A1 (en) | 2001-11-07 |
| ZA200105918B (en) | 2002-07-18 |
| TR200102710T2 (en) | 2002-03-21 |
| EE200100365A (en) | 2002-10-15 |
| NO20013446L (en) | 2001-09-10 |
| JP2002534232A (en) | 2002-10-15 |
| IL144260A (en) | 2006-10-05 |
| KR100517078B1 (en) | 2005-09-26 |
| MXPA01007040A (en) | 2003-07-21 |
| SK9952001A3 (en) | 2002-01-07 |
| AP2001002229A0 (en) | 2001-09-30 |
| EA005662B1 (en) | 2005-04-28 |
| IL144260A0 (en) | 2002-05-23 |
| NO20013446D0 (en) | 2001-07-11 |
| ATE288300T1 (en) | 2005-02-15 |
| DE60017873T2 (en) | 2006-05-18 |
| CZ20012532A3 (en) | 2002-01-16 |
| PT1150744E (en) | 2005-05-31 |
| ES2237412T3 (en) | 2005-08-01 |
| DE60017873D1 (en) | 2005-03-10 |
| HUP0105060A2 (en) | 2002-04-29 |
| BR0007477A (en) | 2003-02-25 |
| EA200100763A1 (en) | 2002-04-25 |
| WO2000041765A1 (en) | 2000-07-20 |
| AU3345800A (en) | 2000-08-01 |
| EP1150744B1 (en) | 2005-02-02 |
| WO2000041765A8 (en) | 2000-08-31 |
| NZ513225A (en) | 2003-11-28 |
| CA2359285A1 (en) | 2000-07-20 |
| US6178351B1 (en) | 2001-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2359285C (en) | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation | |
| US6337995B1 (en) | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation | |
| EP0647150B1 (en) | Apparatus for discrimination of ventricular and supraventricular tachycardia and apparatus for discriminating between a rapid heart rhythm of sinus origin and rapid heart rhythm of non-sinus origin | |
| US6895274B2 (en) | Antitachycardial pacing | |
| US20210205615A1 (en) | Systems and methods for automated capture threshold testing and associated his bundle pacing | |
| US6484057B2 (en) | Pacing methods and devices for treating cardiac arrhythmias and fibrillation | |
| US7139610B2 (en) | Capture management in multi-site pacing | |
| US8449472B2 (en) | Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for prevention of atrial tachyarrhythmias | |
| US7715915B1 (en) | Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for prevention of atrial tachyarrhythmias | |
| WO2004050179A1 (en) | Determining relative depolarization at multiple cardiac sites | |
| US11027136B2 (en) | Systems and methods for automated capture threshold testing and associated his bundle pacing | |
| US7146214B2 (en) | Anti-tachycardia pacing based on multi-site electrograms | |
| US8135464B1 (en) | Painless ventricular rate control during supraventricular tachycardia | |
| AU2004201799B2 (en) | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation | |
| US8145302B1 (en) | Method and system to estimate defibrillation thresholds | |
| US7587243B1 (en) | System and method for verifying capture and/or event sensing during manual threshold evaluations of an implantable cardiac stimulation device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |